However, if side effects persist or worsen over time, it is important to consult with a healthcare provider
Do not use Mounjaro if you: Are pregnant, planning a pregnancy, or breastfeeding Have a personal or family history of medullary thyroid cancer or MEN2 Have a known allergy to tirzepatide or any components of the pen Are under 18 years of age Have a history of eating disorders or unexplained weight loss You should discuss your medical history in detail if you have: Diabetic retinopathy Significant kidney or liver impairment Gastroparesis or delayed stomach emptying A previous episode of pancreatitis Extra caution is required if you use other diabetes treatments

Putting the evidence side by side Here is the blunt comparison: AOD 9604: 2.6 kg weight loss in 12 weeks (best result), failed six clinical trials, development terminated Semaglutide: 15 to 17 percent body weight loss over 68 weeks, FDA approved, thousands of study participants, consistent results across multiple trials There is no way to frame this comparison that puts AOD 9604 on equal footing with semaglutide when it comes to clinical evidence
Researchers believe GLP-1 receptor agonists may also affect stress pathways linked to relapse
Weight loss medications significantly enhance the effectiveness of lifestyle changes, such as a balanced diet and increased physical activity, leading to improved outcomes
doi: 10.3390/ijms24021703